在肺癌中PRKDC表达的预后和潜在治疗作用
Jiani Xiong1,2, Cuimin Deng3, YunRong Fu4
1Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.
Molecular biotechnology
|July 23, 2024
概括
肺癌中PRKDC蛋白的过度表达与生存率低和炎症相关. PRKDC抑制剂显示出作为肺癌治疗的前景,单独或与化疗一起.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 免疫学 免疫学 免疫学
背景情况:
- 蛋白激酶DNA催化子单元 (PRKDC) 对于通过非同类末端连接进行DNA修复至关重要.
- PRKDC功能障碍是癌细胞辐射敏感性的已知生物标志物.
- 肺癌中PRKDC的预后意义和机制性作用仍未得到充分研究.
研究的目的:
- 调查PRKDC在肺腺癌 (LUAD) 的预后价值.
- 探索PRKDC表达与瘤免疫微环境之间的关系.
- 在肺癌模型中评估PRKDC抑制剂的治疗潜力.
主要方法:
- 在LUAD患者队列中分析PRKDC表达.
- 在PRKDC水平和患者生存数据之间的相关性分析.
- 在体外研究评估PRKDC抑制剂在人类肺癌细胞中的疗效.
主要成果:
- 发现PRKDC在LUAD中过度表达.
- 较高的PRKDC表达与不利的患者存活率显著相关.
- 低调PRKDC与炎症瘤免疫特征相关.
- PRKDC抑制剂表现出强大的抗瘤作用,无论是单一治疗还是与西斯普拉丁结合使用.
结论:
- PRKDC作为肺癌的潜在预后生物标志物.
- 在肺癌中,PRKDC是免疫治疗的可行目标.
- 作为肺癌治疗的联合治疗策略,PRKDC抑制剂显示出前景.
更多相关视频
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
16.9K
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.5K
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
